<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02678169</url>
  </required_header>
  <id_info>
    <org_study_id>CLP 9508</org_study_id>
    <nct_id>NCT02678169</nct_id>
  </id_info>
  <brief_title>European Registry on the ACE Reperfusion Catheters and the Penumbra System in the Treatment of Acute Ischemic Stroke</brief_title>
  <acronym>PROMISE</acronym>
  <official_title>A Prospective, Multicenter, Observational, Single-arm European Registry on the ACE Reperfusion Catheters and the Penumbra System in the Treatment of Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Penumbra Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Penumbra Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, single-arm, multicenter, observational registry of the ACE Reperfusion Catheters&#xD;
      and the Penumbra System in Europe. Consecutive patients presenting within 6 hours from&#xD;
      symptom onset with an acute ischemic stroke (within the internal carotid artery and internal&#xD;
      carotid terminus, middle cerebral - M1/M2 segments) due to anterior circulation large vessel&#xD;
      occlusion (LVO) will be treated using the ADAPT technique with thrombo-aspiration as first&#xD;
      intention and site routine practice.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, single-arm, multicenter, observational registry of the ACE Reperfusion Catheters&#xD;
      and the Penumbra System in Europe. Consecutive patients presenting within 6 hours from&#xD;
      symptom onset with an acute ischemic stroke (within the internal carotid artery and internal&#xD;
      carotid terminus, middle cerebral - M1/M2 segments) due to anterior circulation large vessel&#xD;
      occlusion (LVO) will be treated using the ADAPT technique with thrombo-aspiration as first&#xD;
      intention and site routine practice.&#xD;
&#xD;
      The follow-up visit will occur 24 hours, 7-10 days or discharge, 30 days and 90 days&#xD;
      post-procedure and will review patient's functional outcome, quality of life, and adverse&#xD;
      events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Actual">November 2017</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Angiographic revascularization of the occluded target vessel at immediate post-procedure as defined by a TICI 2b or 3 score.</measure>
    <time_frame>Immediate post-procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional patient outcome at 90 days post-procedure as defined by a modified Rankin Score (mRS) 0-2.</measure>
    <time_frame>90 days post-procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of device and procedure related Serious Adverse Events (SAEs) at 24 hours and 30 days from stroke treatment</measure>
    <time_frame>24 hours and 30 days from stroke treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All causes of mortality and morbidity at 90 days</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of embolization in previously uninvolved (or new) territories (ENT) as seen on the final control angiogram at the end of procedure</measure>
    <time_frame>At the end of interventional surgical procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of symptomatic intracranial hemorrhages (sICH) at 24 hours</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of vessel damages at the end of the ADAPT procedure.</measure>
    <time_frame>At the end of the interventional surgical procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIHSS score at 7-10 days post-procedure.</measure>
    <time_frame>7-10 days post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Times to revascularization</measure>
    <time_frame>From symptom onset to various times during the interventional surgical procedure</time_frame>
    <description>From symptom onset to CT-scan/MRI at the institution&#xD;
From CT-scan/MRI at the institution to groin access&#xD;
From groin puncture to final revascularization result.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life: EQ-5D 3L score at 90 days compared to the one at 7-10 days post-procedure.</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heath Economics: Total duration of hospitalization with related healthcare resources</measure>
    <time_frame>Average time frame 3-7 days.</time_frame>
    <description>Health care professionals encountered/consulted before/after intervention&#xD;
Tests performed before/after intervention.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">204</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Penumbra Aspiration System</arm_group_label>
    <description>Penumbra Aspiration System with the ADAPT technique</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Penumbra Aspiration System</intervention_name>
    <description>Penumbra Aspiration System using the ADAPT technique for recanalization of an occlusion large vessel in the brain</description>
    <arm_group_label>Penumbra Aspiration System</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Present with symptoms consistent with an acute ischemic stroke within 6 hours of stroke&#xD;
        symptom onset. Arterial occlusion of the distal intracranial carotid artery (ICA and ICA&#xD;
        terminus) or middle cerebral artery (M1/M2)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  General inclusion criteria:&#xD;
&#xD;
               -  From 18 years of age&#xD;
&#xD;
               -  Present with symptoms consistent with an acute ischemic stroke within 6 hours of&#xD;
                  stroke symptom onset&#xD;
&#xD;
               -  Arterial occlusion of the distal intracranial carotid artery (ICA and ICA&#xD;
                  terminus) or middle cerebral artery (M1/M2)&#xD;
&#xD;
               -  National Institute of Health Stroke Scale (NIHSS) ≥ 2&#xD;
&#xD;
               -  Signed Informed Consent Form.&#xD;
&#xD;
        Imaging inclusion criteria:&#xD;
&#xD;
        • CT ASPECT score from 6 to 10 (&gt;6) or according to MR DWI ASPECT score from 5 to 10 (&gt;5).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  General exclusion criteria:&#xD;
&#xD;
               -  Associated myocardial infarction or severe infection (endocarditis or sepsis)&#xD;
&#xD;
               -  Laboratory evidence of coagulation abnormalities, with an International&#xD;
                  Normalized Ratio (INR) of &gt; 3.0 or platelets count &lt; 40 x109/L or APTT &gt; 50 sec&#xD;
&#xD;
               -  Uncontrolled hypertension (defined as systolic blood pressure &gt; 185 mmHg or&#xD;
                  diastolic blood pressure &gt; 110 mmHg)&#xD;
&#xD;
               -  Baseline glucose &lt; 2.7 or &gt; 22.2 mmol/L&#xD;
&#xD;
               -  Pre-stroke mRS score &gt; 2&#xD;
&#xD;
               -  Seizure at the onset of stroke&#xD;
&#xD;
               -  Arterial tortuosity that would prevent the device from reaching the target vessel&#xD;
&#xD;
               -  Time of stroke symptoms onset unknown&#xD;
&#xD;
               -  Life expectancy less than 90 days prior to stroke onset&#xD;
&#xD;
               -  Females who are pregnant or lactating&#xD;
&#xD;
               -  Known serious sensitivity to radiographic contrast media.&#xD;
&#xD;
        Imaging exclusion criteria:&#xD;
&#xD;
          -  CT/MRI evidence of the following conditions at screening:&#xD;
&#xD;
               -  Significant mass effect with midline shift&#xD;
&#xD;
               -  Evidence of intracranial hemorrhage (ICH), aneurysm, or arteriovenous&#xD;
                  malformation (AVM)&#xD;
&#xD;
          -  Angiographic evidence of tandem extracranial occlusion or an arterial stenosis&#xD;
             proximal to the occlusion that requires treatment prior to thrombus removal. Moderate&#xD;
             stenosis not requiring treatment is not an exclusion criterion.&#xD;
&#xD;
          -  Angiographic evidence of preexisting arterial injury, such as carotid dissection,&#xD;
             complete cervical carotid occlusion, or vasculitis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Schramm, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Schleswig-Holstein, Lübeck, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>January 27, 2016</study_first_submitted>
  <study_first_submitted_qc>February 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2016</study_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

